New ways of controlling cholesterol, including possibly directly injecting “good” HDL cholesterol into patients, need to be studied following the failure of promising treatments from Eli Lilly, Pfizer Inc and Roche Holding AG, according to top heart researchers. Lilly in October halted a 12,000-patient study of its experimental drug evacetrapib, an oral medication that in […]
Semaglutide Demonstrated Superior Improvements in Glycemic Control vs Placebo in Adults with Type 2 Diabetes
BOSTON, April 2, 2016 /PRNewswire/ — Findings from the first phase 3a clinical trial for semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue, demonstrated that treatment with semaglutide, administered once weekly, significantly improved glycemic control compared to placebo in adults with type 2 diabetes previously managed with diet and exercise alone. Results from the SUSTAIN 1 […]
Novartis took its campaign to invigorate sluggish sales of its new heart-failure medicine Entresto to a U.S. cardiologists meeting on Saturday, telling attendees that even clinically stable patients can benefit from the drug. Novartis, which forecasts Entresto will eventually hit $5 billion in annual sales, has seen its introduction last year get off to […]
The world’s first life-saving gene therapy for children, developed by Italian scientists and GlaxoSmithKline, has been recommended for approval in Europe, boosting the pioneering technology to fix faulty genes. The European Medicines Agency (EMA) said on Friday it had endorsed the therapy, called Strimvelis, for a tiny number of children with ADA Severe Combined […]
Array BioPharma Inc said it was abandoning a late-stage study testing its experimental ovarian cancer drug, after an interim analysis showed the trial would likely fail.
The Ankara Chief Prosecutor has launched an investigation into the Turkish unit of Swiss drugmaker Novartis after allegations the company benefited from bribery.
Shortages of essential drugs are becoming increasingly frequent globally, prompting the WHO to suggest minimum prices may be needed to keep some products on the market.
April 1, 2016 By Mark Terry, BioSpace.com Breaking News Staff In what seems to be an early April Fool’s Day joke, a fake website yesterday released a press release under Pfizer (PFE)’s name. The Washington Post then published a story based on the press release, which it has now removed and retracted. The press […]
Janssen R&D Discontinues Fulranumab Phase III Program; Terminates Agreement with Amgen April 1, 2016By Alex Keown, BioSpace.com Breaking News Staff TITUSVILLE, N.J. — Janssen Research & Development, a subsidiary of Johnson & Johnson (JNJ), terminated its Phase III development program for fulranumab in osteoarthritis pain due to a “strategic portfolio prioritization,” the company […]
Global drugmakers said they could cut research spending in Japan due to new rules requiring them to slash prices on some blockbuster drugs, including Gilead Sciences Inc’s highly effective but expensive hepatitis C drug, Sovaldi. Drugmakers such as the Japanese arms of Pfizer Inc and Eli Lilly and Co said the change, which could as […]